Core Viewpoint - The company anticipates achieving revenue of no less than RMB 2.5 billion and net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1] Group 1: Financial Performance - The aesthetic medicine business is expected to generate over RMB 1.4 billion in revenue and over RMB 700 million in segment profit, with both metrics showing an annual growth rate exceeding 90%, becoming the primary revenue and profit driver for the company [1] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Zhu Bio and Hui Sheng Bio, and a transition from investment to revenue generation, improving the company's profit structure [1] - The company maintains a robust financial position with ample cash reserves, implementing multiple rounds of share buybacks and successfully spinning off Xuan Zhu Bio, which enhances equity value and alleviates R&D funding pressure [1] Group 2: Aesthetic Medicine Sector - The company has successfully obtained approvals for several self-developed core products, including various injectables and devices, establishing itself as a comprehensive aesthetic medicine enterprise [2] - The market share of the core product, Le Ti Bao botulinum toxin, has increased to nearly 20%, with partnerships exceeding 8,000 medical aesthetic institutions, driving rapid sales growth of newly launched products [2] - The company is advancing its global strategy by signing an investment agreement with Swiss aesthetic company Suisselle, aiming to penetrate the EU market and solidify its long-term growth foundation [2] Group 3: Pharmaceutical R&D Progress - Rapid advancements in pharmaceutical R&D are evident, with Xuan Zhu Bio's ALK inhibitor and CDK4/6 inhibitor receiving market approvals, and Xuan Yue Ning being included in the national medical insurance directory [3] - The company achieved a successful spin-off listing of Xuan Zhu Bio on the Hong Kong Stock Exchange, providing significant equity value gains and easing R&D investment pressures [3] - This strategic move supports the company's focus on high-growth sectors like aesthetic medicine, facilitating a transition to a new phase of high-quality development [3]

Core Viewpoint - The company expects to achieve revenue of no less than RMB 2.5 billion and net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, representing a year-on-year revenue growth of over 30% [1] Financial Performance Factors - The aesthetic medicine business is projected to achieve revenue exceeding RMB 1.4 billion and segment profit over RMB 700 million, with both revenue and profit growth rates exceeding 90% year-on-year, becoming the largest revenue and profit contributor to the group [2] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Zhu Bio and Hui Sheng Bio, and a transition from investment to revenue generation, improving the group's profit structure [2] - The company maintains a robust financial position with ample cash reserves, implementing multiple rounds of share buybacks and successfully spinning off Xuan Zhu Bio, which enhances equity value and alleviates R&D funding pressure [2] Aesthetic Medicine Segment - The company has successfully obtained approvals for several self-developed core products, including the "Youthful Needle" and "L-Arginine Facial Energy Essence," establishing itself as a comprehensive aesthetic medicine enterprise [3] - The market share of the core product, "Le Ti Bao Botulinum Toxin," has increased to nearly 20%, with partnerships exceeding 8,000 medical aesthetic institutions, driving rapid sales growth of newly launched products [3] - The company is accelerating its global expansion, having signed an investment subscription agreement with Swiss aesthetic company Suisselle, aiming to penetrate the EU market and establish a sustainable growth foundation [3] Pharmaceutical R&D Progress - Rapid advancements in R&D are noted, with Xuan Zhu Bio and Hui Sheng Bio achieving significant milestones, including the approval of ALK inhibitor Xuan Fei Ning and CDK4/6 inhibitor Xuan Yue Ning, with the latter included in the national medical insurance directory [4] - The successful spin-off of Xuan Zhu Bio on the Hong Kong Stock Exchange has provided substantial equity value gains and eased R&D investment pressures, allowing the company to focus resources on high-growth sectors like aesthetic medicine [4]

Core Viewpoint - The company expects to achieve a revenue of no less than RMB 2.5 billion and a net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, reflecting a growth rate of over 30% compared to the previous year [1] Group 1: Financial Performance - The company's aesthetic medicine business is projected to generate over RMB 1.4 billion in revenue and over RMB 700 million in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Bamboo Biotechnology and Hui Sheng Biotechnology, improving the company's profit structure [1] - The company maintains a strong financial position with ample cash reserves, enabling multiple rounds of share buybacks and the successful spin-off of Xuan Bamboo Biotechnology, which alleviates R&D funding pressure [1][4] Group 2: Product Development and Market Position - The company has successfully obtained approvals for several self-developed core products in the aesthetic medicine sector, including various injectables and devices, establishing itself as a comprehensive player in the industry [2] - The market share of the core product, Le Ti Bao botulinum toxin, has increased to nearly 20%, with partnerships extending to over 8,000 aesthetic institutions [2] - The company is accelerating its global expansion, having signed an investment agreement with Swiss aesthetic company Suisselle to introduce its products to the EU market, thereby establishing a closed-loop market presence in Europe and the US [3] Group 3: Future Outlook - The company plans to deepen its strategic focus on aesthetic medicine, with seven products currently in the registration application stage and several others in late clinical phases, ensuring a robust pipeline for future growth [3] - The successful spin-off of Xuan Bamboo Biotechnology in October 2025 is expected to provide significant equity appreciation and support the company's focus on high-growth sectors like aesthetic medicine [4]

Core Viewpoint - Haohai Biological Technology has successfully expanded its product lines in the medical aesthetics and ophthalmology sectors, enhancing its global market presence and growth potential [2]. Group 1: Medical Aesthetics - Haohai's subsidiary Bioxis has successfully launched its Cytosial hyaluronic acid product in Europe, South America, and the Middle East, achieving sales in these regions [2]. Group 2: Ophthalmology - The company's core platform Contamac supplies approximately 17 million optical raw materials annually to contact lens and artificial lens manufacturers in over 70 countries worldwide [2]. - The establishment of these platforms is expected to continuously empower the global layout of the company's product lines, opening up broader development opportunities [2].

Core Viewpoint - The rapid development of the medical beauty industry, particularly "light medical beauty" practices, has raised concerns about health risks due to unqualified practitioners and illegal training programs [1][3] Group 1: Industry Concerns - "Light medical beauty" refers to non-surgical medical beauty projects conducted through injections, phototherapy, and biotechnology, which must be performed in qualified medical institutions by professional medical personnel [3] - There is a growing trend of unqualified businesses exploiting "appearance anxiety" to promote illegal practices, including unauthorized "light medical beauty crash courses" that lead to health risks for the public [1][3] Group 2: Regulatory Emphasis - Non-medical beauty institutions, such as beauty salons and nail shops, are strictly prohibited from offering "light medical beauty" services, emphasizing the importance of prioritizing health and safety over cost [3] - The promotion of "light medical beauty crash courses" often involves misleading marketing tactics that obscure qualifications and simplify techniques, leading to illegal medical practices and the issuance of fake training certificates [3]

2月10日，国家卫生健康委召开新闻发布会，对医疗美容行业中的"轻医美"乱象发出明确警示。近年 来，以注射、激光为代表的非手术类医美项目备受追捧，但部分不良商家借机制造"容貌焦虑"，隐瞒医 疗风险，更在不具备资质的情况下非法开办"轻医美速成班"，导致学员互扎致伤事件频发，给求美者带 来严重健康威胁。 国家卫生健康委强调，"轻医美"本质是医疗行为，必须由持证医务人员在正规医疗机构内操作。生活美 容店、美甲店等场所严禁开展此类项目。同时，社会上流传的"三天学会打针""零基础速成"等培训，往 往涉及非法行医、使用假药劣械、颁发虚假证书等多重违法问题。此外，发布会上，多位专家结合节气 和春节特点，围绕流感防护、春季养生、体重管理等公众健康关切展开全面解读。 严禁生活类美容机构开展"轻医美"项目 "轻医美"是指通过非手术或微创的医学美容手段，实现皮肤护理、抗衰、塑形等美容效果的医美项目， 具有恢复期短、风险相对较低的特点。常见的轻医美项目包括水光针、玻尿酸注射、光子嫩肤等。 据王大燕介绍，当前全国流感疫情总体处于低流行水平，近两月持续下降，流行毒株以甲型H3N2亚型 为主要流行株，乙型Victoria系占比缓慢上升。此外 ...

Core Viewpoint - The National Health Commission of China has raised concerns about the "light medical beauty" industry, highlighting the risks associated with unqualified practitioners and illegal training programs [1] Industry Summary - The "light medical beauty" sector has rapidly developed, primarily involving laser and injectable treatments, attracting many consumers [1] - Unethical businesses exploit "appearance anxiety," concealing the risks of medical beauty procedures and conducting illegal "crash courses" for training [1] - Incidents of injury and disability have occurred due to unqualified individuals performing medical beauty procedures [1] Regulatory Emphasis - "Light medical beauty" refers to non-surgical medical beauty procedures conducted by qualified medical personnel in accredited medical institutions [1] - Non-medical establishments such as beauty salons, hairdressing shops, and nail salons are prohibited from offering "light medical beauty" services [1] Illegal Practices - "Crash courses" in medical beauty often misrepresent medical practices as lifestyle services, misleading consumers through vague qualifications and simplified techniques [1] - Common illegal activities include practicing medicine without a license, fraudulent training, illegal use of medical beauty products and devices, and issuing fake training certificates [1] - The National Health Commission advises the public to be wary of marketing phrases like "three-day crash course" and "zero foundation beginners welcome" [1]

Core Viewpoint - The National Health Commission has raised concerns about the "light medical beauty" industry, highlighting the risks associated with unqualified practitioners and illegal training programs [1][2]. Group 1: Industry Overview - The "light medical beauty" sector has rapidly developed, primarily involving non-surgical procedures such as injections and laser treatments, attracting many consumers [1]. - Unqualified businesses exploit "appearance anxiety," concealing the risks of medical beauty procedures [1]. Group 2: Regulatory Warnings - "Light medical beauty" must be conducted in licensed medical institutions by qualified medical personnel, as it is fundamentally a medical practice [2]. - Non-medical establishments like beauty salons and nail shops are strictly prohibited from offering "light medical beauty" services [2]. Group 3: Illegal Practices - "Light medical beauty crash courses" misrepresent medical practices as lifestyle activities, often leading to illegal medical practices and the issuance of fake training certificates [2]. - Consumers are advised to be cautious of marketing phrases like "three-day crash course" or "zero foundation beginners welcome" [2].

Summary of Conference Call Records Industry Overview - The beauty and personal care sector is showing resilience after adjustments, with strong fundamentals and high historical valuation averages. The sector is expected to benefit from numerous new product launches and marketing activities in Q1 2026, particularly from companies like Proya and Betaini, as well as new materials approved in the medical beauty segment [1][2][3]. Key Points on Companies Proya - Proya's management has been adjusted, and new products are set to launch, with a high confidence level for revenue recovery. The current valuation is around 17 times earnings, significantly lower than the average cosmetics valuation of 25 times, indicating substantial room for valuation recovery [1][3]. - The company has successfully executed marketing strategies, particularly in the sunscreen category, achieving notable results even in off-peak seasons. The launch of upgraded product lines is expected to drive growth [4][5]. Betaini - Betaini has shown a clear turning point since Q4 of last year, with expected double-digit revenue growth and potentially higher profit growth. The new e-commerce head has driven high-quality growth in the main brand's e-commerce business [6]. - New brands like OXYNAT and Winona Baby, along with the acquisition of the Israeli beauty device brand Tripollar, are expected to contribute approximately 1 billion yuan in revenue this year, reducing reliance on a single brand [6]. Aimeike - Aimeike has recently obtained approval for botulinum products, which have significant growth potential. The company has established distribution channels that could lead to strong sales performance, similar to competitors that have achieved over 1 billion yuan in revenue from similar products [7]. Market Trends - The personal care industry has substantial room for growth in e-commerce penetration. Domestic companies are leveraging innovation to increase average transaction values and rapidly grow through high-leverage e-commerce channels. Notable performers include Ru Yuchen and Dengkang Oral Care [8]. - Smaller companies like Jieya, Yanjiang, and Nuobang are gaining attention as they are positioned to benefit from improved downstream demand, leading to performance growth [9]. Noteworthy Companies in the Hong Kong Market - Companies like Juzi, Shangmei, and Maogeping are highlighted for their resilience post-pandemic. Juzi and Shangmei have effectively managed public relations, maintaining brand strength and channel capabilities. Maogeping is recognized for its strong brand power and stable offline channels, despite a higher valuation [10][11]. Investment Outlook - The cosmetics industry is characterized by varying performances among companies. Brands with strong market presence and stable channels, like Maogeping, are expected to show less volatility and maintain growth potential in the long term [12]. This summary encapsulates the key insights from the conference call records, focusing on the beauty and personal care industry, specific company performances, and market trends.

Summary of Conference Call Notes Industry Overview - The focus is on the medical aesthetics (医美) industry, particularly in the context of consumer recovery and spending behavior in 2026 [1][2]. Key Points and Arguments Consumer Behavior - There is a recovery in customer traffic; however, mid-to-high-end female consumers are becoming more rational in their spending, leading to a slight decline in average transaction value by 4% to 6,700 yuan [1][2]. - The business structure is shifting towards light medical aesthetics, resulting in lower single transaction amounts but increased frequency of consumption and shorter decision-making cycles, which benefits cash flow stability [1][2]. Financial Performance - In 2025, revenue is expected to grow, but profits are projected to decline. Notable performance recovery was observed in September and December due to promotional activities, while operations remained flat during non-promotional periods [1][3]. - In January 2026, the company reported a 40% year-on-year revenue growth, attributed to full operational capacity and a pre-Spring Festival demand peak [2][4]. Strategic Focus - The strategy for 2026 emphasizes deepening the existing market and upgrading product categories, with expectations of double-digit growth. The focus will shift from aggressive store expansion to improving efficiency, customer repurchase rates, and customer satisfaction [1][5]. - Growth will primarily rely on minimally invasive and dermatology sectors, with strategies to increase average transaction value and attract new customers [6]. Customer Segmentation - New customers account for 40% and returning customers for 60% of the customer base, with sales proportions being the same. The cost of acquiring new customers is high, ranging from 3,000 to 4,000 yuan [8][9]. - The marketing channels include Xiaohongshu (小红书) and Douyin (抖音), which contribute 30% of traffic, while third-party referrals account for 33% and referrals from existing customers for 17% [8]. Product and Market Trends - The proportion of minimally invasive procedures has increased to 47%, and regenerative materials account for 18% of revenue, reflecting a 5 percentage point increase year-on-year [3][14]. - The market for certain products, such as "素颜萃," is thriving due to high consumer recognition and effective marketing strategies on platforms like Xiaohongshu [16]. Competitive Landscape - The competitive environment is intensifying, with many small to medium-sized institutions struggling, particularly due to rising costs from VAT adjustments. It is anticipated that more small institutions may close [13]. - The company is adapting to VAT policy changes by optimizing material and labor costs and requiring suppliers to issue special invoices for deductions [28]. Marketing and Future Plans - The marketing strategy for 2026 will focus on specific months (January, March, June, September, and December) for heavy promotional activities to drive revenue and profit growth, while February will see reduced spending due to the Spring Festival [32]. - The marketing budget will be adjusted based on the return on investment (ROI) from different platforms, ensuring efficient allocation of resources [33]. Additional Important Insights - The average transaction value for returning customers in January 2026 was 20,900 yuan, remaining stable compared to the previous year [10]. - The overall average transaction value in 2025 was around 7,000 yuan, with a year-on-year growth rate of approximately 10% [29]. - The company is focusing on maintaining relationships with existing customers, as they are seen as a crucial source of future profits [9].